We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a warning letter to Jilin Shulan after an inspection of the firm’s Shulan City, Jilin Province facility revealed significant GMP deviations for active pharmaceutical ingredients. Read More
The FDA hit API manufacturer Reine Lifescience with a warning letter for significant GMP violations observed during a November inspection of its facility in Gujurat, India. Read More
The FDA issued a Form 483 to Noven Pharmaceuticals after observing numerous problems at the transdermal drug manufacturer’s Miami, Florida facility. Read More
The FDA sent out a volley of warning letters to three U.S. distributors of kratom products for sales of unapproved new drugs claiming effectiveness in treating opioid addiction and withdrawal. Read More
The agency found that the firm did not validate its cleaning procedures to make sure no cross contamination occurred in human drugs manufactured at the facility. Read More
A North Carolina drug manufacturing facility is in the hot seat after an October FDA inspection found it was producing topical human drugs and pesticides using the same equipment. Read More
The FDA is on track to complete standardized inspection agreements with every nation in the European Union next summer, one of the agency’s senior international officials said. Read More
The FDA hit API manufacturer Reine Lifescience with a warning letter for significant GMP violations observed during a November inspection of its facility in Gujurat, India. Read More